Dermatologist Preferences for First-Line Therapy of Moderate-to-Severe Psoriasis in Healthy Adults

被引：0

作者：

Wan, Joy ^{[1
]}

Abuabara, Katrina ^{[1
]}

Troxel, Andrea B. ^{[1
]}

Shin, Daniel B. ^{[1
]}

Van Voorhees, Abby S. ^{[1
]}

Bebo, Bruce F., Jr. ^{[2
]}

Krueger, Gerald G. ^{[3
]}

Duffin, Kristina Callis ^{[3
]}

Gelfand, Joel M. ^{[1
]}

机构：

[1] Univ Penn, Sch Med, Philadelphia, PA 19104 USA

[2] Natl Psoriasis Fdn, Portland, OR USA

[3] Univ Utah, Sch Med, Salt Lake City, UT USA

来源：

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2011年 / 20卷

关键词：

D O I：

暂无

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

261

引用

页码：S113 / S113

页数：1

共 50 条

[21] Deucravacitinib in moderate-to-severe psoriasis [J].

Vu, Alan ;

Maloney, Victoria ;

Gordon, Kenneth B. .

IMMUNOTHERAPY, 2022, 14 (16) :1279-1290

[22] COST-EFFECTIVENESS OF FIRST-LINE BIOLOGICS FOR THE MANAGEMENT OF MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].

Beilman, Candace L. ;

Fedorak, Richard N. ;

Halloran, Brendan P. .

GASTROENTEROLOGY, 2019, 156 (06) :S260-S261

[23] Portuguese consensus on first line treatment of moderate-to-severe psoriasis with a non-TNF inhibitor therapy - a delphi methodology [J].

Torres, Tiago ;

Magina, Sofia ;

Lopes, Maria Joao Paiva .

JOURNAL OF DERMATOLOGICAL TREATMENT, 2025, 36 (01)

[24] Ixekizumab for the treatment of moderate-to-severe plaque psoriasis: the first septennium [J].

Carmona-Rocha, Elena ;

Puig, Lluis .

IMMUNOTHERAPY, 2023, 15 (15) :1209-1225

[25] Caspofungin combined with TMP/SMZ as a first-line therapy for moderate-to-severe PCP in patients with human immunodeficiency virus infection [J].

Tian, Q. ;

Si, J. ;

Jiang, F. ;

Xu, R. ;

Wei, B. ;

Huang, B. ;

Li, Q. ;

Jiang, Z. ;

Zhao, T. .

HIV MEDICINE, 2021, 22 (04) :307-313

[26] First-line combination therapy with rituximab and corticosteroids provides a high complete remission rate in moderate-to-severe bullous pemphigoid [J].

Cho, Y. T. ;

Chu, C. Y. ;

Wang, L. F. .

BRITISH JOURNAL OF DERMATOLOGY, 2015, 173 (01) :302-304

[27] Use of systemic and biological therapy in patients with moderate-to-severe psoriasis [J].

Liljendahl, Mie S. ;

Loft, Nikolai ;

Nguyen, Tri-Long ;

Skov, Lone ;

Egeberg, Alexander .

CLINICAL AND EXPERIMENTAL DERMATOLOGY, 2023, 49 (01) :35-41

[28] Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences [J].

Azhar, Aaminah ;

Zaayman, Marcus ;

Silfvast-Kaiser, Annika ;

Kivelevitch, Dario ;

Menter, Alan ;

Paek, So Yeon .

DERMATOLOGIC THERAPY, 2021, 34 (01)

[29] IMMUNOMODULATOR CO-THERAPY IMPROVES MEDICATION PERSISTENCE OF FIRST-LINE ANTI-TUMOR NECROSIS FACTOR AGENTS AND FIRST-LINE VEDOLIZUMAB, BUT NOT SECOND-LINE THERAPY, IN MODERATE-TO-SEVERE ULCERATIVE COLITIS [J].

Pudipeddi, Aviv ;

Ko, Yanna ;

Paramsothy, Sudarshan ;

Leong, Rupert W. .

GASTROENTEROLOGY, 2021, 160 (06) :S343-S344

[30] French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults [J].

Amatore, F. ;

Villani, A. -P. ;

Tauber, M. ;

Viguier, M. ;

Guillot, B. ;

Aubin, Francois ;

Bachelez, Herve ;

Beneton, Nathalie ;

Beylot-Barry, Marie ;

Jullien, Denis ;

Mahe, Emmanuel ;

Paul, Carle ;

Richard, Marie-Aleth .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (03) :464-483

← 1 2 3 4 5 →